Preceding researches have proven that AKF-PD has anti liver fibrosis effects in several animal models (Peng et al., 2014; Peng et al., 2019), Peng et al. (2014) found that AKF-PD can alleviate liver fibrosis by restraining HSC activation and proliferation, and it can regulate the TGF-β1/Smad and MAPK pathways to inhibit the activation of hepatic stellate cells (Peng et al., 2013; Peng et al., 2014; Peng et al., 2019). The gene discussed is TGFB1; the disease is Hepatic fibrosis.